Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Hao Feng, MD., Ph.D.
Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU
Principal Investigator - Jian-jun Zhang, MD
Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU
Study Director - Qiang Xia, MD
Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, China
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Sept 2020
- Primary completion
- 31 Dec 2021
- Completion
- 31 Dec 2025
- Last update posted
- 22 Sept 2020
- Registered enrollment
- 20
- Registry id
- NCT04443322
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.